Shares of semiconductor testing company Aehr Test Systems (NASDAQ: AEHR) rallied 30.6% this week through Friday at 2:33 p.m. EDT, according to data from S&P Global Market Intelligence . Aehr didn't report any financial results this week, but it did announce an order for its wafer test and burn-in machines from a new customer. This customer is also innovating in silicon photonics, a new networking ...
Shares of semiconductor testing company Aehr Test Systems (NASDAQ: AEHR) rallied 30.6% this week through Friday at 2:33 p.m. EDT, according to data from S&P Global Market Intelligence . Aehr didn't report any financial results this week, but it did announce an order for its wafer test and burn-in machines from a new customer. This customer is also innovating in silicon photonics, a new networking technology that many believe will displace copper in AI data centers. Needless to say, the announcement fueled a stock price uptick. Continue reading
Building managers at several major office complexes in Riyadh have instructed tenants to work from home for the next few days, prompting some companies to shift to remote work after Iranian threats against U.
Building managers at several major office complexes in Riyadh have instructed tenants to work from home for the next few days, prompting some companies to shift to remote work after Iranian threats against U.
Fenne/iStock via Getty Images Foreword About Large Cap Value “A large cap stock value ranking from YCharts puts together complementary stocks research strategies. The value ranking looks at the price of a stock relative to a number of measurements that determine intrinsic firm value. Only the largest 10% of companies based on market cap are shown in this portfolio. What it is: The Value Score is a...
Fenne/iStock via Getty Images Foreword About Large Cap Value “A large cap stock value ranking from YCharts puts together complementary stocks research strategies. The value ranking looks at the price of a stock relative to a number of measurements that determine intrinsic firm value. Only the largest 10% of companies based on market cap are shown in this portfolio. What it is: The Value Score is a composite score. It tells you how much you are getting in terms of profits, cash flows, assets, sales, etc. for the stock price that you pay. It is a relative measurement, so it says nothing about the overall level of the market. Rather, it answers the question: "Given the current market level, which stocks give you the most current value for your dollar of investment?" Tens are the most valuable, and 1s are the least. How to use it: Use it to find companies that are selling at a low price relative to their assets and profits. Limitations of the Value Score: Watch out for companies with a lot of uncertainty or bad prospects for the future (e.g., Pharma companies with expiring patents, industries on the decline, etc). About the Ben Graham Formula The Ben Graham Formula strategy contains ultra-stable stocks that will rarely lose money if held over a long period of time. It was developed based on a screen in Graham's book, "The Intelligent Investor." For those who have the book, it is the "Defensive Investor" screen. It selects stocks that are large in terms of sales and total assets, have a strong track record of earnings and dividend payments, have a reasonable current ratio and level of long term debt, and have a low valuation given by PE Ratios and Price to Book Value ratios.” -YCharts While over half of this April collection of GASV is thigh priced, or reveals small, or no, forward looking dividends, fourteen of the twenty-five“safer” lowest-priced dogs of the GASV are buyable. April finds JOYY, Inc ( JOYY ), Hafnia Ltd ( HAFN ), IRSA Inversiones ( IRS ), Weibo Corp ( WB...
The riskiest asset class is converging with one of the safest in a first-of-its-kind financial product: A Bitcoin-backed municipal bond. Bloomberg's Elizabeth Rembert joins Scarlet Fu on "Bloomberg Markets" to discuss. (Source: Bloomberg)
The riskiest asset class is converging with one of the safest in a first-of-its-kind financial product: A Bitcoin-backed municipal bond. Bloomberg's Elizabeth Rembert joins Scarlet Fu on "Bloomberg Markets" to discuss. (Source: Bloomberg)
FactoryTh/iStock via Getty Images Freeport-McMoRan ( FCX ) down 0.9% in Thursday's trading as copper and other base metals fell following President Trump's speech that dampened hopes for a near-term de-escalation in the Middle East war. Goldman Sachs initiated coverage of Freeport-McMoRan ( FCX ) with a Buy rating and $70 price target, believing the company offers best-in-class exposure to structu...
FactoryTh/iStock via Getty Images Freeport-McMoRan ( FCX ) down 0.9% in Thursday's trading as copper and other base metals fell following President Trump's speech that dampened hopes for a near-term de-escalation in the Middle East war. Goldman Sachs initiated coverage of Freeport-McMoRan ( FCX ) with a Buy rating and $70 price target, believing the company offers best-in-class exposure to structural deficits in the copper market with supplemental gold exposure, and that both macro and geopolitical tailwinds should continue to support higher long-term commodity prices, resulting in increased profitability. Additionally, Freeport's ( FCX ) production volumes are at an inflection point, Goldman's Nick Cash and Cecilia Tang said, which should compound the company's profitability in a higher price environment; while this view is widely accepted by the market given the Grasberg mine restart and higher copper prices, the analysts believe Freeport's "asset level margin convexity is underappreciated," which should drive further margin expansion. As a result, the analysts expect a significantly improved operating profile that should lead to higher levels of free cash flow generation, which should increase Freeport's ( FCX ) balance sheet flexibility, and given the company's historical capital allocation distribution, should result in increased returns to shareholders while simultaneously allocating significant capital to growth initiatives. More on Freeport-McMoRan Freeport-McMoRan: The Drawdown Is A Gift Freeport-McMoRan: The Profit Surge Has Barely Started (Rating Upgrade) Freeport-McMoRan Presents at 35th BMO Global Metals, Mining & Critical Minerals Conference Transcript
BeOne Medicines AG (NASDAQ:ONC) ranks among the oversold European stocks to buy. On March 16, Jefferies lowered BeOne Medicines AG (NASDAQ:ONC) to Hold from Buy and reduced its price target to $290 from $420. According to analyst Faisal Khurshid, Brukinsa continues to be one of the strongest assets in hematology and is predicted to continue […]
BeOne Medicines AG (NASDAQ:ONC) ranks among the oversold European stocks to buy. On March 16, Jefferies lowered BeOne Medicines AG (NASDAQ:ONC) to Hold from Buy and reduced its price target to $290 from $420. According to analyst Faisal Khurshid, Brukinsa continues to be one of the strongest assets in hematology and is predicted to continue […]
Douglas Rissing/iStock via Getty Images The Federal Reserve Bank of Atlanta’s GDPNow model on Thursday lowered its estimate for first-quarter real gross domestic product growth to 1.6% from 1.9% a day earlier. That's well below the ~3% level seen in the run-up to the start of the Iran war at the end of February. The decline came after the morning’s international trade report from the U.S. Census B...
Douglas Rissing/iStock via Getty Images The Federal Reserve Bank of Atlanta’s GDPNow model on Thursday lowered its estimate for first-quarter real gross domestic product growth to 1.6% from 1.9% a day earlier. That's well below the ~3% level seen in the run-up to the start of the Iran war at the end of February. The decline came after the morning’s international trade report from the U.S. Census Bureau and the U.S. Bureau of Economic Analysis revealed a widening trade deficit that offset gains in domestic investment. The nowcast for the contribution of net exports to Q1 real GDP growth fell sharply, dropping from -0.23 percentage points to -0.76 percentage points. This decline more than countered an increase in the nowcast of Q1 real gross private domestic investment growth, which rose from 4.9% to 6.6%. Personal consumption expenditures growth also ticked down slightly, falling from 1.5% to 1.4% in the latest estimate. The next GDPNow update is scheduled for Tuesday, April 7. Atlanta Fed More on US Dollar Index, Invesco DB USD Bullish ETF, etc. Dollar Index Rally Runs Out Of Steam- UDN Is A Bearish Dollar Index ETF Hope Dashed, Risk Appetites Slashed Ahead Of Long Holiday Weekend For Many Hope Boosts Risk Appetites And Drags The Greenback Lower Dollar heads for strongest month since 2024 as Iran war drives safe-haven demand Dollar edges higher on safe-haven demand amid Middle East tensions: Currency Recap
Apple Inc. turns 50, evolving from a near-bankrupt company in the 1990s to a $3.6 trillion tech giant. According to Wedbush analyst Dan Ives, the next chapter won't focus on hardware but on AI. Ives highlights Apple's unmatched legacy, from the Macintosh to the iPhone, and its edge in controlling the entire tech stack — chips, software, and services — with 2.5 billion iOS devices globally. This ec...
Apple Inc. turns 50, evolving from a near-bankrupt company in the 1990s to a $3.6 trillion tech giant. According to Wedbush analyst Dan Ives, the next chapter won't focus on hardware but on AI. Ives highlights Apple's unmatched legacy, from the Macintosh to the iPhone, and its edge in controlling the entire tech stack — chips, software, and services — with 2.5 billion iOS devices globally. This ecosystem now positions Apple to lead in AI, but it also raises the stakes. WWDC: The AI Moment Apple
Snap (NYSE:SNAP) stock is down 7% on Thursday, heading toward $4.50 after opening at $4.90. That decline lands on the last trading session before Good Friday as the U.S. stock market is closed tomorrow. The move adds fresh pain to what has already been a brutal stretch for Snap’s loyal investors. Alarmingly, SNAP shares are ... Snap Falls 7% as Activist Pressure and Child Safety Scrutiny Compound ...
Snap (NYSE:SNAP) stock is down 7% on Thursday, heading toward $4.50 after opening at $4.90. That decline lands on the last trading session before Good Friday as the U.S. stock market is closed tomorrow. The move adds fresh pain to what has already been a brutal stretch for Snap’s loyal investors. Alarmingly, SNAP shares are ... Snap Falls 7% as Activist Pressure and Child Safety Scrutiny Compound an Already Brutal Year
Oil prices are surging today. WTI, the primary U.S. oil price benchmark, jumped more than 10% to over $110 a barrel. Meanwhile, Brent, the global benchmark price, rallied 6% to more than $107 per barrel. Crude prices are soaring following President Trump's address to the nation on Wednesday night, where he threatened to hit Iran "extremely hard." Here's a look at what energy investors should do ri...
Oil prices are surging today. WTI, the primary U.S. oil price benchmark, jumped more than 10% to over $110 a barrel. Meanwhile, Brent, the global benchmark price, rallied 6% to more than $107 per barrel. Crude prices are soaring following President Trump's address to the nation on Wednesday night, where he threatened to hit Iran "extremely hard." Here's a look at what energy investors should do right now. Image source: Getty Images. Continue reading
mbbirdy/E+ via Getty Images Canaccord Genuity launched its coverage of Tango Therapeutics ( TNGX ) with a Buy recommendation and a $30 target on Thursday, citing upside from three trial readouts the cancer drug developer is expected to announce this year. One of the readouts will follow a topline analysis from a Phase 1/2 trial designed to test the company’s lead asset, vopimetostat, in pancreatic...
mbbirdy/E+ via Getty Images Canaccord Genuity launched its coverage of Tango Therapeutics ( TNGX ) with a Buy recommendation and a $30 target on Thursday, citing upside from three trial readouts the cancer drug developer is expected to announce this year. One of the readouts will follow a topline analysis from a Phase 1/2 trial designed to test the company’s lead asset, vopimetostat, in pancreatic cancer with MTAP deletions in combination with two RAS(ON) inhibitors developed by Revolution Medicines ( RVMD ). “Tango's strategy to combine with Revolution Medicines' KRAS agents in pancreatic cancer gives a meaningful head start vs. its competitors,” analyst John Newman wrote. “The combination will boost efficacy in MTAP-deleted and KRAS-mutated pancreatic cancer over Revolution Medicines’ KRAS-targeted agents alone,” he added. The analyst projects roughly $800M in peak U.S. sales from vopimetostat in MTAP-deleted non-small cell lung cancer, for which another readout from a Phase 1/2 monotherapy trial is anticipated in 2026. “We expect data here during 2026 with a focus on overall response rate and progression-free survival. Tango expects data to be quite mature, providing a meaningful readout for vopimetostat,” Newman argued. More on Tango Therapeutics Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Tango rises after Q4 results, clinical pact with Erasca Seeking Alpha’s Quant Rating on Tango Therapeutics